Rare genetic disorders
We support innovative biotechs in Italy as they push promising research programs in rare genetic disorders towards preclinical and clinical development.
Our unique collaboration with the Telethon Foundation aims to bring Italian scientific excellence to the world stage. Our mission is to foster a thriving biotech ecosystem in Italy.
Close | Fund | AMT |
---|---|---|
2018 | Sofinnova Telethon Fund | €108 million |
Close: 2018
Fund: Sofinnova Telethon Fund
AMT: €108 million
“We come from the tech transfer world so we understand what it takes to build companies around the expertise at universities and institutions."
“There has to be more willingness to invest in the early stage. If nobody had invested in mRNA technology 10 years ago, I don't think we would have had the Covid vaccine in less than one year.”
Companies
Related News
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as Vice President of the European Society of Gene and Cell Therapy
AAVantgarde Bio appoints Dr. Natalia Misciattelli as Chief Executive Officer
Nephris welcomes discovery of novel pathogenic factor in diabetic kidney disease
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer
AAVantgarde announces the appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical Officer